Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants.
Journal Article (Journal Article)
Hizentra® is a 20% liquid IgG product approved for subcutaneous administration in adults and children greater than 2 years of age. We report two infants less than 2 years in which administration of Hizentra® was safe and effective.
- Gallagher, JL; Patel, NC
- June 2012
Volume / Issue
- 32 / 3
Start / End Page
- 474 - 476
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)